• KinATLAS
  • TranscriptoNET
  • PhosphoNET
  • OncoNET
  • KinaseNET
  • DrugKiNET
  • DrugProNET
  • KiNET-AM
  • Kinetica Online

Updated November 2019

Home | Kinexus | Contact | Credits

Nomenclature

Short Name:
GCK
Full Name:
Mitogen-activated protein kinase kinase kinase kinase 2
Alias:
  • B lymphocyte serine/threonine-protein kinase
  • M4K2
  • MAP4K2
  • MAPK/ERK kinase kinase kinase 2
  • RAB8IP
  • BL44
  • EC 2.7.11.1
  • GCK
  • Germinal center kinase
  • Kinase GCK

Classification

Type:
Protein-serine/threonine kinase
Group:
STE
Family:
STE20
SubFamily:
KHS
 
 

Specific Links

BioCarta Entry: stress pathway
Entrez-Gene Entry: 5871
Entrez-Protein Entry: NP_004570
GeneCards Entry: GCK
KinBASE Entry: GCK
OMIM Entry: 603166
Pfam Entry: Q12851
PhosphoNET Entry: Q12851
Phosphosite Plus Entry: 2489
ScanSite Entry: Q12851
Source Entry: MAP4K2
UCSD-Nature Entry: A001037
UniProt Entry: Q12851
Kinexus Products: GCK
Germinal centre protein-serine kinase; Mitogen-activated protein kinase kinase kinase kinase 2 S170 phosphosite-specific antibody AB-PK646
Germinal centre protein-serine kinase / Mitogen-activated protein kinase kinase kinase kinase 2 (K167-G173, human) pS170 phosphopeptide - Powder PE-04AMQ99

General Links

ClustalW2
GPS-Cuckoo
Human Protein Atlas
Kinase.com
Kinase Research
Kinasource
Kinomer
Netphorest
NetworKIN
Phosida
PhosphoElm
Protein Blast
ScanSite
String

Structure

Mol. Mass (Da):
91556
# Amino Acids:
820
# mRNA Isoforms:
2
mRNA Isoforms:
91,556 Da (820 AA; Q12851); 90,809 Da (812 AA; Q12851-2)
4D Structure:
Interacts with TRAF2, MAP3K1 and RAB8A.
1D Structure:
Retrieve Gene Sequence
Retrieve Full Protein Sequence
Retrieve Catalytic Domain Sequence
 
Subfamily Alignment
subfamily domain
 
Domain Distribution:
Start End Domain
16 273 Pkinase
482 793 CNH
 

Kinexus Products

Click on entries below for direct links to relevant products from Kinexus for this protein kinase.
hiddentext
○ Germinal centre protein-serine kinase; Mitogen-activated protein kinase kinase kinase kinase 2 S170 phosphosite-specific antibody AB-PK646
○ Germinal centre protein-serine kinase / Mitogen-activated protein kinase kinase kinase kinase 2 (K167-G173, human) pS170 phosphopeptide - Powder PE-04AMQ99
 

Post-translation Modifications

For detailed information on phosphorylation of this kinase go to PhosphoNET
Serine phosphorylated:

S8+, S39, S164+, S170+, S227, S298, S328, S385, S394.
Threonine phosphorylated:

T174-, T306, T326, T574, T578, T819.
Tyrosine phosphorylated:

Y27, Y307.
Ubiquitinated:
K32.
 

Distribution

Based on gene microarray analysis from the NCBI
Human Tissue Distribution
% Max Expression:

Mean Expression:

Number of Samples:

Standard Deviation:
% Max Expression:

Mean Expression:

Number of Samples:

Standard Deviation:
  • adipose
    16

    239

    16

    337

  • adrenal
    4

    63

    10

    81

  • bladder
    7

    108

    32

    120

  • brain
    22

    321

    81

    721

  • breast
    47

    685

    11

    484

  • cervix
    0.2

    3

    37

    4

  • colon
    20

    296

    19

    537

  • heart
    49

    727

    53

    1941

  • intestine
    21

    313

    10

    244

  • kidney
    6

    93

    73

    135

  • liver
    5

    72

    43

    88

  • lung
    27

    397

    125

    475

  • lymphnode
    10

    146

    43

    223

  • ovary
    3

    39

    7

    37

  • pancreas
    8

    120

    41

    152

  • pituitary
    0.5

    8

    8

    8

  • prostate
    3

    40

    133

    54

  • salivarygland
    14

    206

    38

    485

  • skeletalmuscle"
    2

    31

    74

    44

  • skin
    24

    358

    56

    408

  • spinalcord
    7

    96

    41

    113

  • spleen
    14

    210

    43

    233

  • stomach
    5

    73

    41

    77

  • testis
    6

    93

    39

    122

  • thymus
    13

    192

    41

    212

  • thyroid
    51

    753

    62

    2425

  • tonsil
    9

    128

    46

    167

  • trachea
    6

    83

    39

    91

  • uterus
    6

    94

    38

    177

  • reticulocytes"
    1.4

    21

    14

    5

  • t-lymphocytes
    100

    1473

    18

    1058

  • b-lymphocytes
    30

    446

    21

    514

  • neutrophils
    10

    144

    80

    335

  • macrophages
    42

    621

    31

    617

  • sperm
    18

    259

    22

    437

 

Evolution

Species Conservation
PhosphoNET % Identity:
PhosphoNET % Similarity:
Homologene %
Identity:
PhosphoNET % Identity:
PhosphoNET % Similarity:
Homologene %
Identity:
  • tableheader
    100

    100

    100
  • tableheader
    99.7

    99.8

    100
  • tableheader
    25.8

    40.6

    99.5
  • tableheader
    -

    -

    95
  • tableheader
    -

    -

    96
  • tableheader
    87.3

    90.6

    95
  • tableheader
    -

    -

    -
  • tableheader
    93.7

    95.6

    94
  • tableheader
    53.3

    70

    92
  • tableheader
    -

    -

    -
  • tableheader
    49.8

    65.8

    -
  • tableheader
    25.7

    40

    -
  • tableheader
    25.9

    41

    81
  • tableheader
    26.2

    41.2

    62
  • tableheader
    -

    -

    -
  • tableheader
    25.3

    43.4

    43
  • tableheader
    -

    -

    -
  • tableheader
    23.9

    40.5

    -
  • tableheader
    -

    -

    -
  • tableheader
    -

    -

    -
  • tableheader
    -

    -

    -
  • tableheader
    -

    -

    36
  • tableheader
    -

    -

    35
  • tableheader
    -

    -

    33
  • tableheader
    -

    -

    -
For a wider analysis go to PhosphoNET Evolution in PhosphoNET
 

Binding Proteins

Examples of known interacting proteins
hiddentext
No. Name – UniProt ID
1 RAB8A - P61006
2 MAP3K11 - Q16584
3 TRAF2 - Q12933
4 MAP2K4 - P45985
 

Regulation

Activation:
NA
Inhibition:
NA
Synthesis:
NA
Degradation:
NA
 

Known Downstream Substrates

For further details on these substrates click on the Substrate Short Name or UniProt ID. Phosphosite Location is hyperlinked to PhosphoNET predictions.
Based on in vitro and/or in vivo phosphorylation data

Substrate Short Name UniProt ID (Human) Phosphosite Location Phosphosite Sequence Effect of Phosphorylation
PRP1 P02810 S24 QDLDEDVSQEDVPLV
 

Protein Kinase Specificity

Matrix of observed frequency (%) of amino acids in aligned protein substrate phosphosites

Kinections GIF
Matrix Type:
Predicted from the application of the Kinexus Kinase Substrate Predictor Version 2.0 algorithm, which was trained with over 10,000 kinase-protein substrate pairs and 8,000 kinase-peptide substrate pairs.
Domain #:
1
 

Inhibitors

For further details on these inhibitors click on the Compound Name and enter it into DrugKiNET or click on the ID's
Based on in vitro and/or in vivo phosphorylation data
Compound Name KD, Ki or IC50 (nM) PubChem ID ChEMBL ID PubMed ID
TTT-3002 IC50 < 2 nM
Bosutinib Kd = 3.1 nM 5328940 288441 22037378
Lestaurtinib Kd = 4.7 nM 126565 22037378
Staurosporine Kd = 8.8 nM 5279 22037378
KW2449 Kd = 11 nM 11427553 1908397 22037378
Syk Inhibitor IV IC50 < 20 nM 10200390
Cdk1/2 Inhibitor III IC50 < 25 nM 5330812 261720 22037377
K-252a; Nocardiopsis sp. IC50 < 25 nM 3813 281948 22037377
SB218078 IC50 < 25 nM 447446 289422 22037377
Sunitinib Kd = 33 nM 5329102 535 22037378
GSK650394A IC50 < 40 nM 25022668 558642
PP242 IC50 < 40 nM 25243800
Wyeth PDK1 Inhibitor Compound 1 IC50 < 40 nM
Alsterpaullone IC50 > 50 nM 5005498 50894 22037377
Alsterpaullone; 2-Cyanoethyl IC50 > 50 nM 16760286 260138 22037377
BML-275 IC50 > 50 nM 11524144 478629 22037377
Gö6976 IC50 > 50 nM 3501 302449 22037377
JAK3 Inhibitor VI IC50 > 50 nM 16760524 22037377
N-Benzoylstaurosporine IC50 > 50 nM 56603681 608533 22037377
PKR Inhibitor IC50 > 50 nM 6490494 235641 22037377
SU11652 IC50 > 50 nM 24906267 13485 22037377
BX795 IC50 < 60 nM 10077147 577784
STO609 IC50 < 60 nM 51371511
Syk Inhibitor IC50 < 60 nM 6419747 104279
Crizotinib Kd = 80 nM 11626560 601719 22037378
LDN193189 IC50 < 80 nM 25195294 513147
Alvocidib Kd = 89 nM 9910986 428690 22037378
AST-487 Kd = 100 nM 11409972 574738 22037378
GSK-3 Inhibitor IX IC50 = 100 nM 5287844 409450
IPA-3 IC50 < 100 nM 521106 472940
JNKIN7 IC50 = 100 nM 57340685
Novartis 12a (PKD1) IC50 = 100 nM
PP121 IC50 < 100 nM 24905142 18849971
Staurosporine aglycone IC50 < 100 nM 3035817 281948
SU6656 IC50 < 100 nM 5353978 605003
SureCN2934634 IC50 = 130 nM 45375865 1080994 19854645
Aloisine A IC50 > 150 nM 5326843 75680 22037377
Kenpaullone IC50 > 150 nM 3820 296586 22037377
NVP-TAE684 Kd = 190 nM 16038120 509032 22037378
Neratinib Kd = 220 nM 9915743 180022 22037378
1;9-Pyrazoloanthrone IC50 > 250 nM 8515 7064 22037377
GSK-3 Inhibitor X IC50 > 250 nM 6538818 430226 22037377
SU9516 IC50 > 250 nM 5289419 258805 22037377
Syk Inhibitor II IC50 > 250 nM 16760670 22037377
Nintedanib Kd = 290 nM 9809715 502835 22037378
Ruboxistaurin Kd = 290 nM 153999 91829 22037378
Canertinib Kd = 330 nM 156414 31965 22037378
Ro-31-8220 IC50 < 400 nM 5083 6291
AG-E-60384 IC50 = 500 nM 6419741 413188 22037377
Dovitinib IC50 = 500 nM 57336746 22037377
Fasudil IC50 = 500 nM 3547 38380 22037377
GSK-3 Inhibitor XIII IC50 = 500 nM 6419766 359482 22037377
H-89 IC50 = 500 nM 449241 104264 22037377
IDR E804 IC50 = 500 nM 6419764 1802727 22037377
SU11274 IC50 = 500 nM 9549297 261641 22037377
Cediranib Kd = 540 nM 9933475 491473 22037378
ETP 46464 IC50 < 600 nM
HG-9-91-01 IC50 < 600 nM
IKK-3 inhibitor IX IC50 < 600 nM 11626927 373751
KIN 112 IC50 < 600 nM
Momelotinib IC50 < 750 nM 25062766 19295546
BI-D1870 IC50 < 800 nM 25023738 573107
K00596a IC50 < 800 nM 9549298 200027
Purvalanol A IC50 < 800 nM 456214 23327
R406 IC50 < 800 nM 11984591
Vemurafenib IC50 < 800 nM 42611257 1229517
A 443654 IC50 < 1 µM 10172943 379300 19465931
Alisertib IC50 > 1 µM 24771867 22016509
Aloisine; RP106 IC50 > 1 µM 44350092 126343 22037377
Amgen TBK 1 inhibitor (Compound II) IC50 = 1 µM
BCP9000906 IC50 > 1 µM 5494425 21156 22037377
Curcumin IC50 = 1 µM 5281767 116438
Flt-3 Inhibitor II IC50 > 1 µM 11601743 377193 22037377
Gö6983 IC50 > 1 µM 3499 261491 22037377
GSK-3b Inhibitor XI IC50 > 1 µM 10020713 272629 22037377
GTP-14564 IC50 > 1 µM 3385203 406375 22037377
GW 843682X IC50 = 1 µM 9826308 514499
GW441756 hydrochloride IC50 = 1 µM 16219400
H-1152; Glycyl IC50 = 1 µM 16760635
IKK-2 Inhibitor IV IC50 = 1 µM 9903786 257167
Indirubin-3′-monoxime IC50 > 1 µM 5326739 22037377
JNJ-7706621 IC50 > 1 µM 5330790 191003 22037377
NU6140 IC50 > 1 µM 10202471 1802728 22037377
PKR Inhibitor; Negative Control IC50 > 1 µM 16760619 22037377
Purvalanol B IC50 = 1 µM 448991 23254
Ruxolitinib IC50 = 1 µM 25126798 1789941
SB431542 IC50 = 1 µM 4521392
Semaxinib IC50 = 1 µM 5329098 276711
TWS119 IC50 > 1 µM 9549289 405759 22037377
VEGFR2 Kinase Inhibitor II IC50 > 1 µM 5329155 88606 22037377
WZ3146 Kd > 1 µM 44607360 20033049
WZ4002 Kd > 1 µM 44607530 20033049
Axitinib Kd = 1.3 µM 6450551 1289926 22037378
Dasatinib Kd = 1.3 µM 11153014 1421 22037378
Vandetanib Kd = 1.6 µM 3081361 24828 22037378
SU14813 Kd = 1.7 µM 10138259 1721885 22037378
A674563 Kd = 1.9 µM 11314340 379218 22037378
Foretinib Kd = 2 µM 42642645 1230609 22037378
TG101348 Kd = 2.1 µM 16722836 1287853 22037378
CHEMBL1240703 Kd = 2.3 µM 52945601 1240703 19654408
CHEMBL606245 IC50 = 2.6 µM 44160269 606245 19884013
Tozasertib Kd = 2.6 µM 5494449 572878 22037378
Pazopanib Kd = 2.7 µM 10113978 477772 22037378
R547 Kd = 2.9 µM 6918852 22037378
A-83-01 IC50 > 3 µM 16218924 1170377
IRAK-4 kinase inhibitor b IC50 > 3 µM
MRT67307 IC50 > 3 µM 44464263
GSK461364A Kd = 3.2 µM 15983966 1908394 22037378
PHA-665752 Kd = 3.6 µM 10461815 450786 22037378
AX20017 IC50 < 4 µM
Cot-Tpl2 Inhibitor Compound 38 (Abbott) IC50 < 4 µM
Cot-Tpl2 Inhibitor Compound 41 (Abbott) IC50 < 4 µM
PD0332991 IC50 < 4 µM 5330286 189963
PF-3644022 IC50 < 4 µM
(5Z)-7-Oxozeaenol IC50 > 4.5 µM 1077979
JNKIN8 IC50 > 4.5 µM 57340686
Tofacitinib Kd = 4.8 µM 9926791 221959 22037378
 

Disease Linkage

General Disease Association:

Cancer, endocrine, and developmental disorders
Specific Diseases (Non-cancerous):

Maturity-onset diabetes of the young, Type 2 (MODY2); Gck-related hyperinsulinism; Gck-related permanent neonatal diabetes mellitus; Diabetes mellitus; Permanent neonatal diabetes mellitus (PNDM); Hypoglycemia; Hyperinsulinemic hypoglycemia; Maturity-onset diabetes of the young (MODY); Hyperglycemia; Hyperinsulinism; Gestational diabetes (GDM); Familial hyperinsulinism; Familial hyperinsulinism (FHI); Hyperinsulinemic hypoglycemia Familial 3; Monogenic diabetes; Pancreatic agenesis; 3-Hydroxyacyl-Coa dehydrogenase deficiency; Greig cephalopolysyndactyly syndrome (GCPS); Leucine-sensitive hypoglycemia of Infancy; Chromosome 7p deletion; Diabetes mellitus, Type 2; Maturity-onset diabetes of the young, Type 1; Diabetes mellitus, noninsulin-dependent, late onset
Comments:
Maturity-Onset Diabetes of the Young, Type 2 is a rare syndrome where insulin production is disrupted, leading to diabetes. Type 2 is an identifier for the maturity onset compared to type 1's juvenile onset. Gck-Related Hyperinsulinism is a rare disease resulting in Gck-mediated abnormally high levels of insulin in the blood. Gck-Related Permanent Neonatal Diabetes Mellitus is a rare disease characterised by abnormally high levels of blood sugar levels. Permanent Neonatal Diabetes Mellitus (PNDM) may be diagnosed through observation of slow growth before birth, epileptic episode, dehydration, hyperglycemia, and failure to thrive in infancy. The rare disease Hyperinsulinemic Hypoglycemia is characterized by high levels of insulin resulting in low blood glucose levels. Familial Hyperinsulinism is a rare condition characterized by high levels of insulin resulting in low blood glucose levels. The rare condition Hyperinsulinemic Hypoglycemia Familial 3 is related to hyperinsulinism due to glucokinase deficiency and to hyperinsulinemic hypoglycemia, familial, 1. Monogenic Diabetes differs from common Diabetes in that Monogenic Diabetes is characterized by a mutation in a single gene. The rare condition Pancreatic Agenesis is notable for the lack of development of a pancreas by the time of childbirth, leading to neonatal diabetes mellitus. 3-Hydroxyacyl-Coa Dehydrogenase Deficiency is characterized by the inability to convert fats to energy and can affect the liver, eye, and brain tissues. Greig Cephalopolysyndactyly Syndrome (GCPS) is a developmental condition where features can include polydactyly (extra toes or fingers), wide big toe or thumb (hallax), and fusion of fingers with a webbing tissue, widely spaced eyes, macrocephaly (large head), and more rarely seizures, intellectual impairment, or developmental delay. Leucine-Sensitive Hypoglycemia of Infancy is a rare condition related to hypoglycemia and permanent neonatal diabetes mellitus. The rare condition Chromosome 7p Deletion is related to Greig Cephalopolysyndactyly Syndrome (GCPS) where limb development is abnormal. Sufferers of Type 2 Diabetes Mellitus have insulin resistance and excess blood glucose levels. Maturity-Onset Diabetes of the Young, Type 1 is related to hypoglycemia and diabetes mellitus. Diabetes Mellitus, Noninsulin-Dependent, Late Onset is characterized by hyperglycemia (high blood glucose levels) induced by a reduced level of insulin production (but not fully abrogated, as would be the case in Type I diabetes).
 
Specific Cancer Types:
Insulinoma
Comments:
Insulinoma is a tumour of the pancreas arising from beta cells, and which will secrete insulin.
 
Gene Expression in Cancers:

The COSMIC website notes an up-regulated expression score for GCK in diverse human cancers of 341, which is 0.7-fold of the average score of 462 for the human protein kinases. The down-regulated expression score of 0 for this protein kinase in human cancers was 100% lower than the average score of 60 for the human protein kinases.
Mutagenesis Experiments:

Insertional mutagenesis studies in mice have not yet revealed a role for this protein kinase in mouse cancer oncogenesis.
Mutation Rate in All Cancers:

Percent mutation rates per 100 amino acids length in human cancers: 0.07 % in 24804 diverse cancer specimens. This rate is only -10 % lower and is very similar to the average rate of 0.075 % calculated for human protein kinases in general.
Frequency of Mutated Sites:

Most frequent mutations with the number of reports indicated in brackets: R192Q (4).
Comments:
No deletions, insertions or complex mutations are noted on the COSMIC website.
 
COSMIC Entry:
GCK
OMIM Entry:
603166
  • Home
  • Top of Page
Copyright 2019 Kinexus BioInformatics Corporation